Induction of local inflammation by recombinant human platelet factor 4 in the mouse

Cell Immunol. 1991 Oct 1;137(1):72-80. doi: 10.1016/0008-8749(91)90057-i.

Abstract

Platelet factor 4 (PF-4) has been shown to be chemotactic for neutrophils and monocytes in vitro. To assess whether these observations have in vivo relevance, we tested the ability of recombinant human PF-4 (rPF-4) to induce acute and chronic dermal inflammation in the mouse. When injected as a single dose intradermally, rPF-4 induced an acute inflammatory response that peaked at 6 to 12 hr and which resolved by 36 hr. Injection of an equivalent amount of cytochrome c, buffer alone, or an amino-terminal PF-4 peptide failed to elicit a significant inflammatory response; however, the carboxy-terminal PF-4 peptide retained proinflammatory properties. The inflammatory infiltrate induced by a single injection of either rPF-4 or the 41 amino acid carboxy-terminal peptide was composed of neutrophils and smaller numbers of mononuclear cells. Repeated injection of rPF-4 resulted in nearly equal numbers of neutrophils and mononuclear cells. Moreover, marked dermal fibrosis developed after only 5 days of daily injection of rPF-4. Although relatively high concentrations of rPF-4 were required to elicit an inflammatory response, these concentrations may be locally attainable during platelet aggregation. Our findings thus support the hypothesis that PF-4 may contribute to the development of inflammatory responses at sites of platelet aggregation.

MeSH terms

  • Animals
  • Dose-Response Relationship, Drug
  • Female
  • Indomethacin / pharmacology
  • Inflammation / chemically induced*
  • Inflammation / pathology
  • Leukocytes, Mononuclear / pathology
  • Mice
  • Mice, Inbred Strains
  • Neutrophils / pathology
  • Platelet Factor 4 / antagonists & inhibitors
  • Platelet Factor 4 / pharmacology*
  • Recombinant Proteins
  • Skin / pathology

Substances

  • Recombinant Proteins
  • Platelet Factor 4
  • Indomethacin